Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy ResMed stock | $205.85
Learn how to easily invest in ResMed stock.
ResMed Inc is a medical instruments & supplies business based in the US. ResMed shares (RMD) are listed on the NYSE and all prices are listed in US Dollars. ResMed employs 7,770 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in ResMed
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – RMD – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
- RMD shares summary
- Compare share dealing platforms
- Is RMD stock a buy or sell?
- Stock performance over time
- Can I short RMD shares?
- Is RMD suitable for ethical investing?
- Are RMD shares over-valued?
- ResMed's financials
- How volatile are RMD shares?
- Does ResMed pay a dividend?
- Have RMD shares ever split?
- Other common questions
ResMed stock price (NYSE: RMD)Use our graph to track the performance of RMD stocks over time.
ResMed shares at a glance
|Latest market close||$205.85|
|52-week range||$164.77 - $269.96|
|50-day moving average||$246.90|
|200-day moving average||$211.74|
|Wall St. target price||$228.33|
|Dividend yield||$1.56 (0.59%)|
|Earnings per share (TTM)||$3.13|
Buy ResMed shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy ResMed stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
ResMed price performance over time
|1 week (2021-07-21)||N/A|
|1 month (2021-07-01)||-16.96%|
|3 months (2021-04-30)||9.51%|
|6 months (2021-01-28)||N/A|
|1 year (2020-07-28)||N/A|
|2 years (2019-07-28)||N/A|
|3 years (2018-07-28)||N/A|
|5 years (2016-07-28)||N/A|
Is ResMed under- or over-valued?
Valuing ResMed stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of ResMed's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
ResMed's P/E ratio
ResMed's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 86x. In other words, ResMed shares trade at around 86x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
ResMed's PEG ratio
ResMed's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 5.6411. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into ResMed's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
ResMed's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1 billion.
The EBITDA is a measure of a ResMed's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$3.1 billion|
|Operating margin TTM||29.18%|
|Gross profit TTM||$1.8 billion|
|Return on assets TTM||12.4%|
|Return on equity TTM||18.42%|
|Market capitalisation||$39.3 billion|
TTM: trailing 12 months
Shorting ResMed shares
There are currently 1.1 million ResMed shares held short by investors – that's known as ResMed's "short interest". This figure is 24.9% down from 1.4 million last month.
There are a few different ways that this level of interest in shorting ResMed shares can be evaluated.
ResMed's "short interest ratio" (SIR)
ResMed's "short interest ratio" (SIR) is the quantity of ResMed shares currently shorted divided by the average quantity of ResMed shares traded daily (recently around 666863.52201258). ResMed's SIR currently stands at 1.59. In other words for every 100,000 ResMed shares traded daily on the market, roughly 1590 shares are currently held short.
However ResMed's short interest can also be evaluated against the total number of ResMed shares, or, against the total number of tradable ResMed shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ResMed's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 ResMed shares in existence, roughly 10 shares are currently held short) or 0.0074% of the tradable shares (for every 100,000 tradable ResMed shares, roughly 7 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against ResMed.
Find out more about how you can short ResMed stock.
ResMed's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like ResMed.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
ResMed's total ESG risk score
Total ESG risk: 29.05
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and ResMed's overall score of 29.05 (as at 12/31/2018) is nothing to write home about – landing it in it in the 50th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like ResMed is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
ResMed's environmental score
Environmental score: 7.42/100
ResMed's environmental score of 7.42 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that ResMed is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
ResMed's social score
Social score: 14/100
ResMed's social score of 14 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that ResMed is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
ResMed's governance score
Governance score: 12.64/100
ResMed's governance score puts it squarely in the 4th percentile of companies rated in the same sector. That could suggest that ResMed is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
ResMed's controversy score
Controversy score: 1/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. ResMed scored a 1 out of 5 for controversy – the highest score possible, reflecting that ResMed has managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
|Total ESG score||29.05|
|Total ESG percentile||50.28|
|Environmental score percentile||4|
|Social score percentile||4|
|Governance score percentile||4|
|Level of controversy||1|
ResMed share dividends
Dividend payout ratio: 39.2% of net profits
Recently ResMed has paid out, on average, around 39.2% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.59% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), ResMed shareholders could enjoy a 0.59% return on their shares, in the form of dividend payments. In ResMed's case, that would currently equate to about $1.56 per share.
While ResMed's payout ratio might seem fairly standard, it's worth remembering that ResMed may be investing much of the rest of its net profits in future growth.
ResMed's most recent dividend payout was on 16 June 2021. The latest dividend was paid out to all shareholders who bought their shares by 11 May 2021 (the "ex-dividend date").
Have ResMed's shares ever split?
ResMed's shares were split on a 2:1 basis on 30 August 2010. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your ResMed shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for ResMed shares which in turn could have impacted ResMed's share price.
ResMed share price volatility
Over the last 12 months, ResMed's shares have ranged in value from as little as $164.7746 up to $269.96. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while ResMed's is 0.3041. This would suggest that ResMed's shares are less volatile than average (for this exchange).
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries.
Stocks similar to ResMed
ResMed in the news
Earnings Estimates Rising for ResMed (RMD): Will It Gain?
Stocks That Hit 52-Week Highs On Friday
The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs
Frequently asked questionsWhat percentage of ResMed is owned by insiders or institutions?
Currently 0.802% of ResMed shares are held by insiders and 70.961% by institutions. How many people work for ResMed?
Latest data suggests 7,770 work at ResMed. When does the fiscal year end for ResMed?
ResMed's fiscal year ends in June. Where is ResMed based?
ResMed's address is: 9001 Spectrum Center Boulevard, San Diego, CA, United States, 92123 What is ResMed's ISIN number?
ResMed's international securities identification number is: US7611521078 What is ResMed's CUSIP number?
ResMed's Committee on Uniform Securities Identification Procedures number is: 761152107
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert